Merck, Inc.
🇵🇭Philippines
MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)
Phase 2
Completed
- Conditions
- Seasonal Allergies
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2015-12-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 766
- Registration Number
- NCT00533208
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 497
- Registration Number
- NCT00533481
A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00533598
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
Phase 3
Terminated
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: OdanacatibDrug: Placebo for OdanacatibDietary Supplement: Vitamin D3Dietary Supplement: Calcium carbonate
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16071
- Registration Number
- NCT00529373
A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)
Phase 2
Completed
- Conditions
- Sarcopenia
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 170
- Registration Number
- NCT00529659
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
Phase 3
Terminated
- Conditions
- AtherosclerosisMyocardial InfarctionMyocardial Ischemia
- Interventions
- Drug: PlaceboDrug: Vorapaxar
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12944
- Registration Number
- NCT00527943
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
Phase 3
Completed
- Conditions
- AtherosclerosisIschemiaMyocardial InfarctionCerebrovascular AccidentPeripheral Arterial Disease
- Interventions
- Drug: PlaceboDrug: Vorapaxar
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26449
- Registration Number
- NCT00526474
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
Phase 3
Completed
- Conditions
- HIV InfectionsAcquired Immunodeficiency Syndrome
- Interventions
- Drug: PlaceboDrug: Vicriviroc
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 506
- Registration Number
- NCT00523211
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
Phase 3
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: infliximabDrug: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT00521924
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Phase 2
Completed
- Conditions
- Cervical CancerVulvar CancerVaginal CancerGenital WartsHuman Papillomavirus Infection
- First Posted Date
- 2007-08-24
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 511
- Registration Number
- NCT00520598
© Copyright 2025. All Rights Reserved by MedPath